EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors

Rhianna Gasson, James A Roper iD, Robert J Slack iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25126756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Rhianna Gasson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Galecto Biotech AB, Stevenage Bioscience Catalyst, Stevenage SG1 2FX, UK. Hauptthemen laut MEDLINE: Erythrocytes, Hemagglutination, Galectins, Galectin 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galecto Biotech AB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Galectins are a family of beta-galactoside-binding proteins that are characterised by their carbohydrate recognition domain (CRD) and include galectin-1 and galectin-3. These galectins have been implicated in numerous diseases due to their pleiotropic nature, including cancer and fibrosis, with therapeutic inhibitors being clinically developed to block the CRD. One of the early methods developed to characterise these galectins was the hemagglutination of red blood cells. Although it is insightful, this approach has been hampered by a lack of sensitivity and accurate quantification of the agglutination observed. In this study, we aimed to validate a more precise and quantitative method to enable the further investigation of differences between galectins in respect to agglutination induction in different blood groups, as well as the characterisation of small molecule inhibitors. Quantification of hemagglutination was shown to be optimal using U-bottom plates imaged and analysed with FIJI ImageJ rather than flat-bottom plates read for absorbance on an optical density plate reader. Galectin-3-induced red blood cell agglutination efficacy increased significantly from blood group O to A to B. However, for both the galectin-1 monomer and concatemer, a more comparable effect was observed between blood group B and O, but with more potent effects than in blood group A. Inhibition assays for both galectin-3 and galectin-1 induced-hemagglutination were able to demonstrate clear concentration responses and expected selectivity profiles for a set of small-molecule glycomimetics, confirming the historical profiles obtained in biochemical binding and functional cellular assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErythrocytesHemagglutinationGalectinsGalectin 1HumansGalectin 3Agglutination TestsHemagglutination TestsAgglutination

Stichwörter der Autor:innen

assay optimisationgalectin-1galectin-3red blood cell agglutination

Substanzen

GalectinsGalectin 1Galectin 3

Autor:innen und Institutionen

  • Galecto Biotech AB, Stevenage Bioscience Catalyst, Stevenage SG1 2FX, UK.

ORCID-Profile: James A Roper, Robert J Slack

Förderung

  • Galecto Biotech AB

Zitieren

APA

Gasson, R., Roper, J. A., & Slack, R. J. (2024). A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126756

Vancouver

Gasson R, Roper JA, Slack RJ. A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126756

BibTeX
@article{Gasson2024,
  author = {Gasson, Rhianna and Roper, James A and Slack, Robert J},
  title = {A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25126756}
}
Kostenlos starten →